HHS allocates Lilly therapeutic to treat patients with mild to moderate COVID-19

11. November 2020 EHR, EMR, Health, HIPAA 0
The U.S. Department of Health and Human Services today announced plans to allocate initial doses of Eli Lilly and Company’s investigational monoclonal antibody therapeutic, bamlanivimab, which received emergency use authorization from the U.S. Food and Drug Administration November 9 for the treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19. On October ...